A Strong Start For Amvuttra, But Alnylam Bides Time On Heart Results And US Price Control Plans

Company Will Await Full Readout In 2024

 
• By Andrew McConaghie

Alnylam has scrapped plans for an interim analysis of its all-important HELIOS-B study of its new ATTR therapy, hoping that a 2024 readout will be more compelling, while the US Inflation Reduction Act has put the brakes on development in another indication.

Alnylam building
Alnylam's HELIOS-B study is expected to read out in early 2024, allowing it to take on Pfizer's Vyndaqel and Vyndamax. • Source: Alamy

More from Business

More from Scrip